The narrative that casts Republicans as inherently hostile to science has become deeply ingrained, particularly in recent years. Yet, a closer examination of federal funding patterns reveals a more complex reality – one where the GOP has historically been a significant, and often more substantial, supporter of scientific investment than commonly perceived. This isn’t to dismiss legitimate concerns about the current administration’s actions, but to highlight a crucial disconnect between rhetoric and budgetary practice that demands a more nuanced understanding. The question isn’t simply whether science is supported, but how and by whom, and the answers challenge prevailing assumptions about partisan divides.
In research published last fall in Science, my colleagues Nic Fishman and Leah Rosenstiel and I analyzed four decades of federal science appropriations – from 1980 to 2020 – encompassing 171 budget accounts across 27 agencies, including the National Institutes of Health (NIH), NASA, the National Science Foundation (NSF), and even Pentagon research and development programs. What we found was striking: when Republicans controlled either the House of Representatives or the presidency, science funding was, on average, approximately $150 million higher per budget account than under Democratic control of the House, and $100 million higher under a Republican president. These weren’t marginal differences; they persisted across numerous statistical tests, independent of broader economic conditions or overall budget size. Specifically, we observed consistently higher appropriations for NIH, increased funding for the Centers for Disease Control and Prevention (CDC) under Republican presidents, and even marginally greater support for NASA and NSF.
For the past year, we questioned whether our findings represented a historical anomaly, a relic of a Republican Party that no longer exists. The Trump administration’s proposed cuts – a staggering 40% reduction to NIH, attempts to cap indirect-cost recovery for research institutions, and politically motivated interference in grant allocations – certainly suggested a fundamental shift. The administration’s actions, including stalling grants, clearing out agency leadership, and imposing political approval requirements, appeared to dismantle the long-standing compact between the government and the scientific community. However, Congress, with a Republican majority in both chambers, systematically rejected these most extreme proposals.
Based on the original theatlantic.com report.
The recently signed funding bill provides a compelling example. Rather than enacting the proposed 40% cut to NIH, lawmakers increased its budget by roughly $415 million, bringing the total to $48.7 billion – virtually unchanged from the previous year. Crucially, the bill included targeted funding for critical research areas like cancer, Alzheimer’s disease, and the BRAIN Initiative focused on neurotechnologies. Beyond simply maintaining funding levels, Congress actively constrained executive overreach, reaffirming NIH’s autonomy in setting indirect-cost rates, limiting the agency’s ability to favor multi-year awards at the expense of new research, and mandating regular briefings on grant awards and terminations to ensure transparency and accountability. Similar patterns emerged at NASA, facing a 1.6% cut instead of the proposed 24%, and NSF, experiencing a 3.4% decrease rather than the drastic 57% reduction initially sought.
It’s important to clarify what these numbers do and do not tell us. Our database tracks recurring operating expenses allocated to science and research, encompassing both grant-making and contracts with corporations. It doesn’t capture the direct impact of funding freezes imposed on specific universities like Harvard, Columbia, and Penn by the administration. Nevertheless, the Republican-led Congress largely adhered to the patterns identified in our earlier research, prioritizing science funding, protecting research infrastructure, and asserting control over agency operations. This outcome, improbable just six months ago, represents a significant institutional resilience.
The sustained funding of science isn’t solely driven by partisan enthusiasm, but by the inherent structure of the appropriations process, specifically the power vested in the House majority. Our data reveal that funding levels correlate with control of the House and the presidency, but not the Senate. Republican appropriators, it appears, have consistently funded science not in spite of their priorities, but because of them – recognizing the vital link between scientific advancement and economic competitiveness, technological leadership, and national security. While the Trump administration’s antagonism towards science is undeniably concerning, it hasn’t fundamentally altered the Republican Party’s position on science funding in the same way it has reshaped stances on trade or immigration.
Looking ahead, the critical question isn’t whether the current administration will continue to propose cuts – it almost certainly will. The more important question is whether the Republican-led Congress will continue to act as a check on those proposals, upholding its historical commitment to scientific investment. Scientists and research advocates should shift their focus from lamenting perceived Republican hostility to proactively engaging with Republican appropriators, particularly in the House, to ensure that this crucial funding stream remains secure. The 2026 budget cycle will be a crucial test: will the pattern of institutional resilience continue, or will the administration’s efforts to undermine science funding finally gain traction? The future of American research may well depend on the answer.
